Safety and preliminary efficacy of ivaltinostat, an HDAC inhibitor, plus capecitabine in patients with pretreated metastatic pancreatic adenocarcinoma (mPDAC): Results of a phase Ib study.

Authors

Christos Fountzilas, Roswell Park Comprehensive Cancer Center, NY
Andrew H. Ko, University of California, San Francisco
Erkut Hasan Borazanci, HonorHealth Research Institute, AZ
James Thomas D'Olimpio, Clinical Research Alliance, NY
Joel R Hecht, University of California, Los Angeles
Shou-Ching Tang, LSU Health Sciences Center - New OrleansFollow
Anthony F. Shields, Wayne State University, MI
Mohamad Adham Salkeni, Virginia Cancer Specialists Research Institute
Glenn C Michelson, CG Pharmaceuticals Inc.
Lorna Liganor, CG Pharmaceuticals Inc.
Gene Cho, CG Pharmaceuticals Inc.
Sangsook Ahn Cho, CG Pharmaceuticals Inc.
Evan Justin Walker, University of California, San Francisco

Document Type

Conference Proceeding

Publication Date

1-27-2025

Publication Title

Journal of Clinical Oncology

Abstract

2025 ASCO Genitourinary Cancers Symposium; January 23 - 25, 2025; San Francisco, CA

First Page

742

Volume

43

Publisher

American Society of Clinical Oncology

Comments

Abstract 742

Recommended Citation

Fountzilas, Christos; Ko, Andrew H.; Borazanci, Erkut Hasan; D'Olimpio, James Thomas; Hecht, Joel R; Tang, Shou-Ching; Shields, Anthony F.; Salkeni, Mohamad Adham; Michelson, Glenn C; Liganor, Lorna; Cho, Gene; Cho, Sangsook Ahn; and Walker, Evan Justin, "Safety and preliminary efficacy of ivaltinostat, an HDAC inhibitor, plus capecitabine in patients with pretreated metastatic pancreatic adenocarcinoma (mPDAC): Results of a phase Ib study." (2025). School of Medicine Faculty Publications. 3614.
https://digitalscholar.lsuhsc.edu/som_facpubs/3614
10.1200/JCO.2025.43.4_suppl.742